These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22624650)

  • 41. Characterization of heparin impurities with HPLC-NMR using weak anion exchange chromatography.
    Limtiaco JF; Jones CJ; Larive CK
    Anal Chem; 2009 Dec; 81(24):10116-23. PubMed ID: 19911825
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NMR of heparin API: investigation of unidentified signals in the USP-specified range of 2.12-3.00 ppm.
    Lee SE; Chess EK; Rabinow B; Ray GJ; Szabo CM; Melnick B; Miller RL; Nair LM; Moore EG
    Anal Bioanal Chem; 2011 Jan; 399(2):651-62. PubMed ID: 20949261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heavy metal binding to heparin disaccharides. II. First evidence for zinc chelation.
    Whitfield DM; Sarkar B
    Biopolymers; 1992 Jun; 32(6):597-619. PubMed ID: 1643265
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of heparin origin by HPLC quantitation of disaccharide components.
    Mascellani G; Liverani L; Bianchini P
    Farmaco; 1996 Apr; 51(4):247-54. PubMed ID: 8645412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Isolation of heparin and chondroitin sulfate from animal tissue by an ion exchange method].
    Ivankin AN; Nekliudov AD
    Prikl Biokhim Mikrobiol; 1998; 34(6):692-7. PubMed ID: 9929895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive analysis of heparinase derived heparin-products using two-dimensional liquid chromatography coupled with mass spectrometry.
    Chen L; Ouyang Y; Yan N; Guo Y; Yi L; Sun Y; Liu D; Zhang Z
    J Chromatogr A; 2021 Apr; 1643():462049. PubMed ID: 33743327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Method to detect contaminants in heparin using radical depolymerization and liquid chromatography-mass spectrometry.
    Li G; Cai C; Li L; Fu L; Chang Y; Zhang F; Toida T; Xue C; Linhardt RJ
    Anal Chem; 2014 Jan; 86(1):326-30. PubMed ID: 24364596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural variation in the linkage region of pharmaceutical heparin arising from oxidative treatments during manufacture.
    Urso E; Mantione G; Sala F; Yates EA; Guerrini M; Naggi A
    Carbohydr Res; 2022 Apr; 514():108540. PubMed ID: 35276531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simple fluorescence assay for quantification of OSCS in heparin.
    Lühn S; Schiemann S; Alban S
    Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heparin characterization: challenges and solutions.
    Jones CJ; Beni S; Limtiaco JF; Langeslay DJ; Larive CK
    Annu Rev Anal Chem (Palo Alto Calif); 2011; 4():439-65. PubMed ID: 21469955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis and characterization of heparin impurities.
    Beni S; Limtiaco JF; Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):527-39. PubMed ID: 20814668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.
    Bhaskar U; Hickey AM; Li G; Mundra RV; Zhang F; Fu L; Cai C; Ou Z; Dordick JS; Linhardt RJ
    Biotechnol Prog; 2015; 31(5):1348-59. PubMed ID: 26147064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of heparins with different relative molecular masses (from 11,600 to 1600) by various analytical techniques.
    Volpi N
    J Chromatogr; 1993 Dec; 622(1):13-20. PubMed ID: 8120108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oversulfated chondroitin sulfate is not the sole contaminant in heparin.
    Pan J; Qian Y; Zhou X; Pazandak A; Frazier SB; Weiser P; Lu H; Zhang L
    Nat Biotechnol; 2010 Mar; 28(3):203-7; author reply 207-11. PubMed ID: 20212477
    [No Abstract]   [Full Text] [Related]  

  • 56. [Advances in heparin structural analysis by chromatography technologies].
    Ouyang Y; Yi L; Qiu L; Zhang Z
    Se Pu; 2023 Feb; 41(2):107-121. PubMed ID: 36725707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMR methods to monitor the enzymatic depolymerization of heparin.
    Limtiaco JF; Beni S; Jones CJ; Langeslay DJ; Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):593-603. PubMed ID: 20814667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [NMR analysis of a contaminant in heparin].
    Yamaguchi H; Shinagawa M; Shimba N; Miyano H; Suzuki E
    Yakugaku Zasshi; 2008 Oct; 128(10):1513-5. PubMed ID: 18827473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a novel structure in heparin generated by potassium permanganate oxidation.
    Beccati D; Roy S; Yu F; Gunay NS; Capila I; Lech M; Linhardt RJ; Venkataraman G
    Carbohydr Polym; 2010 Oct; 82(3):699-705. PubMed ID: 25147414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On-line NMR detection of microgram quantities of heparin-derived oligosaccharides and their structure elucidation by microcoil NMR.
    Korir AK; Larive CK
    Anal Bioanal Chem; 2007 Aug; 388(8):1707-16. PubMed ID: 17607565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.